ASX RHY blood test beats US tech but remains mispriced
RHY.AX stock analysis: 476% potential upside targets major biotech breakout — buy or sell 👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends In this deep dive, we break down Rhythm Biosciences Limited (RHY.AX) and its transition from a pre-revenue R&D entity into a commercial diagnostic enterprise via its breakthrough ColoSTAT bowel cancer blood test and geneType platform. With its revolutionary ColoSTAT test delivering a validated 90.3% sensitivity and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.